StockMarketWire.com - Collagen Solutions' recent progress on its key initiatives for this fiscal year will be highlighted by chief executive Jamal Rushdy as the annual general meeting later today.

He will say: "First, we have now enrolled 12 of 15 (80%) of the patients scheduled in the open label extension study for ChondroMimetic, an osteochondral scaffold for the repair of cartilage defects in the knee.

"We expect final data collection and analysis by the end of the calendar year, with a submission for CE-mark certification to follow.

"We have strengthened our tissue business by recently expanding our abattoir capacity by approximately 80%, and additional abattoir qualifications and yield improvement initiatives are in process.

"Our core business momentum is continuing with four new early-stage customer deals in the first quarter of the fiscal year, including two new tissue customers.

"This new business will help underpin our overall anticipated growth which is weighted to the second half of our fiscal year.

"Finally, our US facility consolidation plans are on track, which will provide improved collaboration and cost-savings to be used for further R&D investment.

"We expect to merge these sites next month in our new facility near Minneapolis, Minnesota."


At 9:11am: [LON:COS] Collagen Solutions Plc share price was +0.26p at 5.13p



Story provided by StockMarketWire.com